Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders

Trends in Pharmacological Sciences

Volumn 26, Issue 1, 2005, Pages 27-35

  Youdim, Moussa B H ^a   Buccafusco, Jerry J ^b,c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 5 (PIPERIDIN 1 YL) 1 PENTANONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 FLUORO A METHYL(1,1' BIPHENYL) 4 ACETIC ACID 4 (NITROOXY)BUTYL ESTER; 3 (4 HYDROXY 3 METHOXYPHENYL) 2 PROPENOIC ACID 4 (NITROOXY)BUTYL ESTER; 3 [4 [2 FLUORO A METHYL(1,1' BIPHENYL) 4 ACETYLOXY] 3 METHOXYPHENYL] 2 PROPENOIC ACID 4 (NITROOXY)BUTYL ESTER; 5 (4 PROPARGYLPIPERAZIN 1 YLMETHYL) 8 HYDROXYQUINOLINE; 5 (N METHYL N PROPARGYLAMINOMETHYL) 8 HYDROXYQUINOLINE; 5 [4 (2 HYDROXYETHYL)PIPERAZIN 1 YLMETHYL] 8 HYDROXYQUINOLINE; ALPHA ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); BENZOFURANE 3 CARBOXYLIC ACID 8 METHYL 8 AZABICYCLO[3.2.1]OCT 3 YL ESTER; CATECHOL METHYLTRANSFERASE; CHOLINERGIC RECEPTOR; CHOLINESTERASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; FLURBIPROFEN 4 NITROXYBUTYL ESTER; HLA 20; IRON CHELATING AGENT; JWSUSC 75IX; LADOSTIGIL; LEVODOPA; M 31; MEMANTINE; N (QUINUCLINDIN 3 YL) 2 (1 METHYL 1H INDOL 3 YL) 2 OXOACETAMIDE; N PROPARGYL 3 (8 HYDROXYQUINOLIN 5 YL)ALANINE ETHYL ESTER; NCX 2057; NCX 2216; NEUROPROTECTIVE AGENT; NITRIC OXIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; RASAGILINE; RS 17017; RS 56812; RS 66331; UNCLASSIFIED DRUG; UNINDEXED DRUG; VK 28;

ALZHEIMER DISEASE; APOPTOSIS; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEPRESSION; DISEASE COURSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; MOLECULAR DYNAMICS; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIDE EFFECT; TREATMENT INDICATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 11144245220     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.11.007     Document Type: Review

References (78)

1. J.J. Buccafusco, and A.V. Terry Jr Multiple CNS targets for eliciting beneficial effects on memory and cognition J. Pharmacol. Exp. Ther. 295 2000 438 446
2. J.L. Guillou Differential activation of adenylyl cyclases by spatial and procedural learning J. Neurosci. 19 1999 6183 6190
3. J.J. Buccafusco The cholinergic hypothesis - past and present J.J., Buccafusco Cognitive Enhancing Drugs 2004 Birkhäuser Berlin 1 10
4. A.V. Terry Jr Drugs that target serotonergic receptors J.J., Buccafusco Cognitive Enhancing Drugs 2004 Birkhäuser Berlin 79 88
5. X.D. Li, and J.J. Buccafusco Role of α7 nicotinic acetylcholine receptors in the pressor response to intracerebroventricular injection of choline: blockade by amyloid peptide Aβ1-42 J. Pharmacol. Exp. Ther. 309 2004 1206 1212
6. A.V. Egorov Graded persistent activity in entorhinal cortex neurons Nature 420 2002 173 178
7. P. Remy, and Y. Samson The role of dopamine in cognition: evidence from functional imaging studies Curr. Opin. Neurol. 16 Suppl. 2 2003 S37 S41
8. M.S. Lidow D1 dopamine receptors in the mouse prefrontal cortex: Immunocytochemical and cognitive neuropharmacological analyses Synapse 47 2003 101 108
9. J.S. Franowicz, and A.F. Arnsten Treatment with the noradrenergic alpha-2 agonist clonidine, but not diazepam, improves spatial working memory in normal young rhesus monkeys Neuropsychopharmacology 21 1999 611 621
10. B. Vitiello Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans Neuropsychopharmacology 16 1997 15 24
11. C.E. Stern Medial temporal and prefrontal contribution to working memory tasks with novel and familiar stimuli Hippocampus 11 2001 337 346
12. P.E. Gilbert Memory for spatial location: Role of the hippocampus in mediating spatial pattern separation J. Neurosci. 18 1998 804 810
13. G. Riedel Reversible neural inactivation reveals hippocampal participation in several memory processes Nat. Neurosci. 2 1999 898 905
14. E. Sybirska Prominance of direct entorhinal-CA1 pathway activation in sensorimotor and cognitive tasks revealed by 2-DG functional mapping in nonhuman primates J. Neurosci. 20 2000 5827 5834
15. S.D. Vann Fos imaging reveals differential patterns of hippocampal and parahippocampal subfield activation in rats in response to different spatial memory tests J. Neurosci. 20 2000 2711 2718
16. S.M. Zola Impaired recognition memory in monkeys after damage limited to the hippocampal region J. Neurosci. 20 2000 451 463
17. H. Eichenbaum How does the brain organize memories Science 277 1997 330 332
18. F. Vargha-Khadem Differential effects of early hippocampal pathology on episodic and semantic memory Science 277 1997 376 380
19. B.J. Knowlton A neostriatal habit learning system in humans Science 273 1996 1399 1402
20. E. Teng Contrasting effects on discrimination learning after hippocampal lesions and conjoint hippocampal-caudate lesions in monkeys J. Neurosci. 20 2000 3853 3863
21. A. Bechara Double dissociation of conditioning and declarative knowledge relative to the amygdala and hippocampus in humans Science 269 1995 1115 1118
22. J.J. Buccafusco Cognitive effects of nicotinic cholinergic agonists in non-human primates Drug Dev. Res. 38 1996 196 203
23. J.T. Little Combined nicotinic and muscarinic blockade in elderly normal volunteers: cognitive, behavioral, and physiologic responses Neuropsychopharmacology 19 1998 60 69
24. V. Haroutunian Restoration of cholinomimetic activity by clonidine in cholinergic plus noradrenergic lesioned rats Brain Res. 507 1990 261 266
25. A.V. Terry Jr Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys Cereb. Cortex 3 1993 304 312
26. K. Elrod Nicotine enhances delayed matching-to-sample performance by primates Life Sci. 43 1988 277 287
27. A.V. Terry Jr Ranitidine analog, JWS-USC-75IX, enhances memory-related task performance in rats Drug Dev. Res. 47 1999 97 106
28. W.B. Rowe Long-term effects of BIBN-99, a selective muscarinic M2 receptor antagonist, on improving spatial memory performance in aged cognitively impaired rats Behav. Brain Res. 145 2003 171 178
29. J.C. Cassel, and H. Jeltsch Serotonergic modulation of cholinergic function in the central nervous system: Cognitive implications Neuroscience 69 1995 1 41
30. I.G. McKeith Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB) Report of the consortium on DLB international workshop Neurology 47 1996 1113 1124
31. R.H. Perry Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly J. Neurol. Sci. 95 1990 119 139
32. M. Weinstock Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease CNS Drugs 12 1999 307 323
33. D. Aarsland Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep J. Neuropsychiatry Clin. Neurosci. 13 2001 374 379
34. M.W. Jann Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease Pharmacotherapy 20 2000 1 12
35. R. Moretti Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up J. Eur. Neurol. 8 2001 361 362
36. E. Tandberg The occurrence of depression in Parkinson's disease. A community-based study Arch. Neurol. 53 1996 175 179
37. S.C. Newman The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample J. Affect. Disord. 52 1999 169 176
38. A.M. Palmer Possible neurotransmitter basis of behavioral changes in Alzheimer's disease Ann. Neurol. 23 1988 616 620
39. M. Weinstock TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease J. Neural Transm. Suppl. 60 2000 157 169
40. J. Sterling Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease J. Med. Chem. 45 2002 5260 5279
41. J.J. Buccafusco Potential cognitive actions of (n-propargyl-(3r)- aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task Neuroscience 119 2003 669 678
42. M.B. Youdim Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B Br. J. Pharmacol. 132 2001 500 506
43. M.B.H. Youdim Rasagiline; an anti-parkinson drug with neuroprotective activity Expert Rev. Neurotherapeutics 3 2003 737 749
44. Parkinson Study Group A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease Arch. Neurol. 61 2004 561 566
45. Y. Sagi Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor J. Neurochem. 86 2003 290 297
46. M. Weinstock A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 555 561
47. M. Weinstock Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression Psychopharmacology (Berl.) 160 2002 318 324
48. M. Weinstock Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits Neuropharmacology 43 2002 999 1005
49. M.B. Youdim The anti-parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo Ann. New York Acad. Sci. 931 2001 450 458
50. W. Maruyama Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022 J. Neural Transm. Suppl. 60 2000 171 186
51. W. Maruyama Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor Neurosci. Lett. 341 2003 233 236
52. W. Huang Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse Eur. J. Pharmacol. 366 1999 127 135
53. Z. Speiser Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders J. Neural Transm. Suppl. 52 1998 287 300
54. M. Yogev-Falach Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline FASEB J. 16 2002 1674 1676
55. O. Weinreb Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members FASEB J. 18 2004 1471 1473
56. W. Gsell Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type J. Neurochem. 64 1995 1216 1223
57. J. Saura Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative radioautography Neuroscience 62 1994 15 30
58. M.P. Mattson Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders Ann. New York Acad. Sci. 1012 2004 37 50
59. K.A. Jellinger The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease Drugs Aging 14 1999 115 140
60. M.B. Youdim Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28 Ann. New York Acad. Sci. 1012 2004 306 325
61. D. Berg Brain iron pathways and their relevance to Parkinson's disease J. Neurochem. 79 2001 225 236
62. D.B. Shachar Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats Neuropharmacology 46 2004 254 263
63. D. Kaur Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease Neuron 37 2003 899 909
64. E.M. Mutisya Cortical cytochrome oxidase activity is reduced in Alzheimer's disease J. Neurochem. 63 1994 2179 2184
65. W.D. Parker Abnormalities of the electron transport chain in idiopathic Parkinson's disease Ann. Neurol. 26 1989 719 723
66. D.S. Cassarino, and J.P. Bennett An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration Brain Res. Brain Res. Rev. 29 1999 1 25
67. S. Mandel Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs Trends Pharmacol. Sci. 24 2003 184 191
68. Grunblatt, E. et al. Genomic profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm. (in press)
69. M.B.H. Youdim Novel bi-functional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases J. Neural Transm. 111 2004 1455 1471
70. R. Furlan A nitric oxide releasing derivative of flubiprofen inhibits experimental autoimmune encephalomyelitis J. Neuroimmunol. 150 2004 10 19
71. G.L. Wenk Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid J. Neurochem. 89 2004 484 493
72. J. Corey-Bloom Galantamine: a review of its use in Alzheimer's disease and vascular dementia Int. J. Clin. Practice 57 2003 219 223
73. T. Weiser Drugs that target ionotropic excitatory amino acids J.J., Buccafusco Cognitive Enhancing Drugs 2004 Birkhäuser Basel 89 96
74. S.A. Areosa, and F. Sherriff Memantine for dementia Cochrane Database Syst. Rev. 1 2003 CD003154
75. Tariot, P.N. (2004) Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J. Am. Med. Assoc. 291, 317-324
76. G.E. Meredith A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation Parkinsonism Relat. Disord. 10 2004 191 202
77. K. Jellinger Brain iron and ferritin in Parkinson's and Alzheimer's diseases J. Neural Transm. Park. Dis. Dement. Sect. 2 1990 327 340
78. E. Grunblatt Gene expression analysis in N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine J. Neurochem. 78 2001 1 12